Quidel Corporation announced the addition of several executives to enhance its management team in the areas of science, technology and business development. Tim Stenzel, M.D., Ph.D. has been named Chief Scientific Officer. Working with Dr. Stenzel in the area of technology assessment is Judi Tilghman, Ph.D., who joined Quidel in July. Larry Mimms, Ph.D. joined Quidel to lead the research and development function, and Ratan Borkar has been named Vice President of Business Development.

“I am pleased to announce these important executive additions that enhance the Quidel management team,” said Douglas C. Bryant, President and Chief Executive Officer. “These individuals bring a wealth of experience and talent to our organization in a number of key areas that are critical to ensuring our continued long-term growth.”

Beginning in September, Dr. Stenzel will be responsible for technology assessment as well as implementing Quidel’s molecular diagnostics strategy. Dr. Stenzel most recently was Vice President and Chief Medical Officer for molecular diagnostics company Asuragen. He has also held senior positions at Abbott Laboratories and Duke University, where he established Duke’s molecular lab capabilities. Dr. Stenzel received his M.D. and Ph.D. from Duke University.

Dr. Tilghman, Vice President, Technology Assessment most recently worked for EMD Chemicals, Luminex and Sigma Aldrich in strategic planning and business development roles. Dr. Tilghman has broad management experience in strategic planning, business development, product development, and technology acquisition and integration. She has a Ph.D. in molecular biology from the University of Illinois at Chicago.

Dr. Mimms, Vice President, Research and Development, has held a number of senior executive positions with Gen-Probe and most recently headed his own company, VDx LLC, which focused on the development of a rapid HIV diagnostic test. His doctorate is in biochemistry from Duke University.

Mr. Borkar comes to Quidel from J.P. Morgan where he worked in investment banking, most recently as Vice President, Healthcare Group covering companies in molecular diagnostics, life sciences and clinical research areas. Mr. Borkar has an MBA from the University of Michigan.

Source: Quidel Corporation